Company: INMB
Filing Date: 2025-04-21
Form Type: DEF 14A
Source: 0001213900-25-033742
Chunk: 34

Company: Inmune Bio, Inc.
Filing Date: 2025-04-21
Form: DEF 14A
Chunk 34
---
 has one or more of its executive officers serving as a member of our compensation committee. Nominating and Corporate Governance Committee The nominating and corporate governance committee, among other things, is responsible for: •reviewing and assessing the development of the executive officers, and considering and making recommendations to the Board of Directors regarding promotion and succession issues; •evaluating and reporting to the Board of Directors on the performance and effectiveness of the directors, committees, and the Board of Directors as a whole; •working with the Board of Directors to determine the appropriate and desirable mix of characteristics, skills, expertise, and experience, including diversity considerations, for the full Board of Directors and each committee; •annually presenting to the Board of Directors a list of individuals recommended to be nominated for election to the Board of Directors; •reviewing, evaluating, and recommending changes to the Company’s corporate governance policies and committee charters; •recommending to the Board of Directors individuals to be elected to fill vacancies and newly created directorships; •overseeing the Company’s compliance program, including the code of conduct; and •overseeing and evaluating how the Company’s corporate governance and legal and regulatory compliance policies and practices, including leadership, structure, and succession planning, may affect the Company’s major risk exposures. The Board of Directors has adopted a written charter setting forth the authority and responsibilities of the nominating and corporate governance committee. The nominating and corporate governance committee consists of Marcia Allen, Kelly Ganjei and Scott Juda, J.D. Marcia Allen is the chairman of the nominating and corporate governance committee. During 2024, the nominating and corporate governance committee had no meetings. Board of Director Meetings and Attendance Our Board of Directors met in person and telephonically 4 times during 2024 and also approved resolutions or acted by unanimous written consent 9 times. Each of the then -membersof our Board of Directors was present at 75% or more of the meetings of the Board of Directors and committees held in 2024 . 24

EXECUTIVE COMPENSATION The following table sets forth the compensation for the Company’s fiscal years ended December 31, 2024 and 2023 earned by or awarded to, as applicable, our principal executive officer, principal financial officer and the Company’s other most highly compensated executive officers as of December 31, 2024. In this proxy statement, we refer to such officers as the Company’s “Named Executive Officers.”

| Name and Principal Position |     | Year |     |